Preclinical
MP-5342 (LDHA inhibitor)
XtalPi with META Pharmaceuticals: company profile
IND-enabling per company
Since , the date of the source that reports this phase.
Summary
MP-5342 is a LDHA inhibitor from XtalPi with META Pharmaceuticals. The source describes it as small molecule (oral). It is being developed for autoimmune disease. Per the company, it was at IND-enabling as of Sep 9, 2026. The AI role named in the source is molecule design. The latest dated source is from Sep 9, 2026.
Built only from the sources listed on this page.
Facts
- Company
- XtalPi with META Pharmaceuticals
- Indication
- Autoimmune disease
- Therapeutic area
- Immunology and inflammation
- Modality
- Small molecule (oral)
- AI role
- Molecule design
- Phase in the source
- IND-enabling, as of Sep 9, 2026
- Phase source
- X only
- Board column
- Preclinical
- Trial record
- none (preclinical)
AI evidence
AI source: Company
“XtalPi contributed computational modeling, including free-energy perturbation calculations,”
Milestone timeline
-
Official X post: IND-enabling
Spot an error? Tell me and I'll fix it.